Theoretical framework = not mentionedSetting = Docrates Cancer Center, Oulu University HospitalPopulation = cancer mixedSample size = 37Median age = 61 yFemale = 35.1%Race and ethnicity = not mentionedTreatment type = anti–PD1, anti–PD-L1, and anti–CTLA-4. The gene discussed is RPL17; the disease is cancer.